The Japan Next-Generation Sequencing market was valued at USD 458.33 million in 2025 and is projected to reach approximately USD 2,269.91 million by 2035, growing at a robust CAGR of 17.35%. This growth reflects advancements in genomics and increasing adoption in healthcare research and diagnostics.

Japan Next-generation Sequencing Market Statical Scope

Due to rising demand for precision medicine , increasing cancer and genetic disorder testing, strong government support for genomics research, lower sequencing costs, and why the reduction of advances to diagnostics in hospitals and resource centres.

It is advancing through faster high-throughput sequencers, improved long-term technology powered by data analysis, automated sample vibration, and cloud-based bioinformatics platforms. Companies are also launching compact, cost-efficient systems that enhance accuracy and reduce turnaround time. These innovations are supporting wider use of genomic testing in cancer diagnosis and rare disease protection in preseason medicines across hospital laboratories and research institutes in Japan.

Japan Next-generation Sequencing Market Share, By Technology, 2025 (%)

• Whole Genome Sequencing- The segment dominated the market with a 28% share, due to growing research use of rare diseases studies, population genomics programmes and declining sequencing costs.
• Whole Exome Sequencing- The segment dominated the market with a 23% share, because it offers cost-effective analysis of coding genes supporting rare disease diagnosis, cancer research and clinical studies.
• Targeted Sequencing & Resequencing- The segment dominated the market with a 49% share, due to lower costs, faster results, high accuracy and strong demand for cancer mutation analysis and clinical diagnostics.

Japan Next-generation Sequencing Market Share, By Product, 2025 (%)

• Consumables- The segment dominated the market with a 65% share, because recent kits, chips and sample prep materials require frequent repeat purchases for every sequencing run.
• Platforms- The segment accounted for 35% of the total market share, due to rising adoption of advanced sequencer laboratory upgrades automation needs an expanding genomic research capacity.

Japan Next-generation Sequencing Market Share, By Application, 2025 (%)

• Oncology- The segment dominated the market with a 33% share, due to increasing cancer cases demand for biomarkers testing, personalized therapies and early tumor mutation detection.
• Clinical Investigation- The segment accounted for 18% of the total market share, due to strong use in cancer testing, rare disease diagnosis, precision medicine, and hospital-based genetic screening programs.
• Reproductive Health- The segment accounted for 13% of the total market share, due to growing use of prenatal screening, embryo testing, carrier screening, and rising awareness of inherited disorders.

Japan Next-generation Sequencing Market Share, By Work Flow, 2025 (%)

• Pre-Sequencing- The segment accounted for 19% of the total market share, due to essential sample preparation, laboratory construction quality control steps, and growing testing volumes in laboratories.
• Sequencing- The segment dominated the market with a 64% share, because core sequencing runs drive instrument usage. every agent consumption, faster sample processing and routine clinical and resource demand.
• NGS Data Analysis- The segment accounted for 17% of the total market share, due to rising genomic datasets demand for bioinformatics tools, cloud platforms and accurate clinical interpretation.

Japan Next-generation Sequencing Market Share, By End Use, 2025 (%)

• Academic Research- The segment dominated the market with a 38% share, due to strong university funding for genomics projects, disease studies and widespread use in scientific innovations.
• Clinical Research- The segment accounted for 20% of the total market share, due to rising biomarker studies, precision medicine trials, hospital collaborations and increasing genomic validation programs.
• Hospitals & Clinics- The segment accounted for 18% of the total market share, due to growing use of genetic testing, cancer diagnostics, prenatal screening and personalized treatment planning.
• Pharma & Biotech Entities- The segment accounted for 16% of the total market share, due to rising drug discovery biomarker research clinical trials and precision medicine development activities.
• Other Users- The segment accounted for 8% of the total market share, due to usage by forensic labs, agricultural genomics veterinary testing and independent diagnostics service providers.

Top Companies in the Japan Next-generation Sequencing Market

• Illumina, Inc
• QIAGEN
• Thermo Fisher Scientific, Inc
• BGI
• Pacific Biosciences
• Bio Rad Laboratories
• Oxford Nanopore Technologies, Inc
• Myriad Genetics. Inc.
• Agilent Technologies Inc
• Eurofins Scientific

Segments Covered in the Report

By Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing
• Others

By Product

• Consumables
• Platforms

By Application

• Oncology
• Clinical Investigation
• Reproductive Health
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Agrigenomics & Forensics
• Consumer Genomics

By Workflow

• Pre-Sequencing
• Sequencing
• NGS Data Analysis

By End-use

• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other users